939981-39-2

Basic information

• Product Name: [(4R,5S)-4,5-Bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]methanone
• Synonyms: [(4R,5S)-4,5-Bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]methanone;p53 and MDM2 proteins-interaction-inhibitor;Methanone, [(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-(1,1-diMethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-diMethyl-1H-iMidazol-1-yl][4-[3-(Methylsulfonyl)propyl]-1-piperazinyl]-;p53 inhibitor;RG7112;RO5045337 (RG7112);RG7112(RO5045337)
• CAS NO: 939981-39-2
• Molecular Formula: C₃₈H₄₈Cl₂N₄O₄S
• Molecular Weight: 727.78312
• Mol File: 939981-39-2.mol

Chemical Properties

• Appearance: /
• Density: 1.23
• Solubility: ≥36.4 mg/mL in DMSO; insoluble in H2O; ≥31.87 mg/mL in EtOH
• CAS DataBase Reference: [(4R,5S)-4,5-Bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]methanone(CAS DataBase Reference)
• NIST Chemistry Reference: [(4R,5S)-4,5-Bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]methanone(939981-39-2)
• EPA Substance Registry System: [(4R,5S)-4,5-Bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]methanone(939981-39-2)

Safety Data

• Hazardous Substances Data: 939981-39-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
RG-7112 is used as an MDM2 antagonist for the biological study of single mouse analysis on the evaluation of alternative in vivo drug screening methodologies. Its ability to increase p53 levels and inhibit cancer cell proliferation makes it a promising candidate for cancer therapy, particularly in the development of targeted treatments for tumors with wild-type or mutant p53 expression.
Used in Cancer Research:
RG-7112 is used as a research tool in cancer research to study the role of MDM2 in the regulation of p53 and its potential as a therapeutic target in various types of cancer. It can also be used to investigate the mechanisms of action and resistance to MDM2 inhibitors, as well as to identify potential synergistic effects with other cancer therapies.
Used in Drug Development:
RG-7112 can be used in the development of new drugs targeting the MDM2-p53 pathway, with the aim of improving the efficacy and selectivity of cancer treatments. It may also be used in combination with other drugs to enhance their therapeutic effects and overcome resistance in cancer cells.
Used in Preclinical Studies:
RG-7112 is used in preclinical studies to evaluate its safety, pharmacokinetics, and pharmacodynamics, as well as to assess its potential for use in clinical trials. These studies can provide valuable information on the optimal dosing regimens, potential side effects, and therapeutic window of RG-7112, which can inform the design of future clinical trials and the development of new MDM2 inhibitors.

Relevant articles and documents

Deconstruction of a nutlin: Dissecting the binding determinants of a potent protein-protein interaction inhibitor

Protein-protein interaction (PPI) systems represent a rich potential source of targets for drug discovery, but historically have proven to be difficult, particularly in the lead identification stage. Application of the fragment-based approach may help tow

Application of PAT tools for the safe and reliable production of a dihydro-1 H -imidazole

The application of two Process Analytical Technology (PAT) tools was studied and implemented for the safe and reliable synthesis of an advanced intermediate (4S,5R-7) of a member of the dihydro-1H-imidazole (1) class of compounds. Real time data were generated using ReactIR to track the complete breakdown of phosgene precursors (2) to phosgene (3) and confirm the absence of these hazardous materials prior to batch transfer operations. In addition, the chiral resolution by crystallization of rac7 was monitored by a Lasentec FBRM probe-based system. Implementation of the latter helped to track the crystallization process to minimize the risk of cocrystallization of undesired isomer 4R,5S-7.